A negative trailing P/E is not a valuation signal in itself, so the more relevant read is the 1.65 price-to-sales multiple against a 2026Q2 net margin of -80.5%, which implies the market is capitalizing revenue that does not yet convert to profit. The 1.86 price-to-book ratio sits above what a shrinking equity base of $33.0M would normally support, suggesting the price reflects a pipeline or option value that the reported figures do not themselves demonstrate. Without EV/EBITDA, forward earnings, or FCF multiples, and with peers such as Beam Therapeutics also reporting negative earnings, the valuation cannot be benchmarked to either its own history or a profitable peer group, which warrants further investigation before drawing any conclusion about relative cheapness.

The gap between gross margin and operating margin is the central analytical issue, since a 76.5% gross margin in 2026Q2 that converts to -75.3% operating margin implies roughly $22M to $24M of quarterly R&D and SG&A spending absorbing nearly all gross profit. The single positive quarter in 2025Q4, with a 35.9% operating margin on a 91.4% gross margin, appears to reflect a revenue spike rather than a structural shift, so it should not be extrapolated. Relative to the peer group, where Trustmark reports a 20.0% net margin, CDXS is structurally unprofitable at the operating level, and the gap looks more structural than temporary given the recurring fixed cost pattern.

The ROE deterioration is amplified by a shrinking equity denominator, which fell by roughly 58% over the period, so part of the more negative ROE reflects a smaller base rather than purely worse absolute losses. The one positive ROIC print of 13.6% in 2025Q4 coincided with a revenue spike and should be treated as non-recurring until repeated. Compared with peer ROIC of -31.1% at Beam Therapeutics and 7.1% at Trustmark, CDXS sits in the loss-making cohort, and the persistent negative ROIC suggests invested capital is not yet generating economic returns.

A rise in D/E from 0.55 to 2.20 reflects mainly the decline in book equity rather than new borrowing, since total debt stayed near $70M, which raises the question of how much buffer remains before equity approaches zero. Interest coverage is missing or negative in most quarters, so the data does not allow a conclusion about debt service comfort, and this data gap itself warrants attention. The D/EBITDA reading of 4.52 in 2025Q4 is only available for one quarter and reflects a single profitable period, so refinancing risk should be monitored as equity continues to erode.

Because inventory is a small share of current assets given DIO of roughly 47 to 59 days, the quick ratio of 2.99 sits close to the current ratio and suggests liquidity is not dependent on inventory conversion. However, the current ratio has swung from 5.82 to 3.06 across the window, and continued cash burn could compress this cushion faster than the ratio alone implies. Under a severe stress scenario where operating losses persist at 2026Q2 levels, the position would depend on how quickly the $27.2M cash balance is consumed, which the supplied data does not project.